Gilles Montalescot, ACTION Study Group, Paris

Slides:



Advertisements
Similar presentations
ARCTIC investigators COI D ISCLOSURE FOR D R. M ONTALESCOT : Research Grants to the Institution or Consulting/Lecture Fees from Abbott Vascular, Astra-Zeneca,
Advertisements

PCI - A prospective, randomized, double- blind substudy of patients undergoing PCI in the CURE trial.
Prasugrel vs ticagrelor in acute coronary syndromes
Novel antithrombotic agents in acute coronary syndromes: better or worse than P2Y12 inhibitors Giuseppe Biondi Zoccai Sapienza Università di Roma
Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Jacob A. Udell, MD, MPH, Marc P. Bonaca, MD, MPH, Jean-Philippe Collet, MD, PhD, A. Michael Lincoff, MD, Dean J. Kereiakes, MD, Francesco Costa, MD, Cheol.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
ReoPro ® in NSTEMI and STEMI Trials Harald Vangerow, MD Clinical Research Physician Eli Lilly UK.
PRODIGY Objective Study Design Primary Composite Endpoint
Pocket Guide to Anticoagulation in AF & Dual Antiplatelet Therapy in ACS Rumi Jaumdally 2015 This brief presentation will summarise the recently published.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Acute Coronary Syndrome: In Hospital Antiplatelet Management
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
CHU TIMONE, Marseille, FR
_________________ Caitlin M. Gibson, PharmD, BCPS
Disclosures Speaker’s bureau: Research support: Consulting: Equity
Stent Thrombosis and Optimal Duration of DAPT
Denise Sutter, PharmD, BCPS
Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.
CRT 2017: Putting LAA closure in the age of DOACs into perspective
When should aspirin be dropped from triple therapy?
Randomisation before planned PCI with DES (n=2500)
Should We Preload STEMI Patients with Antiplatelet Therapy?
Short versus Long DAPT Studies – An Academic View
Polypharmacy Anticoagulation: AF meets PCI
The Impact of prolonged antiplatlelet therapy Following DES
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
Sinai Center for Thrombosis Research Baltimore, Maryland, U.S.A.
ARCTIC-INTERRUPTION 2-year- Versus 1year Duration of Dual-Antiplatelet Therapy After DES implantation The randomized ARCTIC-Interruption Study JP Collet.
DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.
The ANTARCTIC investigators
(p < for group 1 or 2 vs. group 3)
Learning Objectives. Learning Objectives Variable Response to Clopidogrel.
Atrial Fibrillation and PCI
Glenn N. Levine et al. JACC 2016;68:
Achieving Long-Term Protection Post-MI
PAD Patients vs Post-ACS Patients:
Glenn N. Levine et al. JACC 2016;68:
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.
Nat. Rev. Cardiol. doi: /nrcardio
Antiplatelet Therapy and Secondary Prevention
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
Giuseppe Biondi Zoccai University of Turin, Turin, Italy
NOACS: Emerging data in ACS/IHD
The Management of ACS “Updated Perspectives and Goals” Rafid F. Al-Aqeedi FIBMS ( Med ), MRCP (London), DM ( Int.Card.), FACC, FESC Consultant Interventional.
ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.
Would you recommend extending DAPT >1 year post-MI?
Preventive Angioplasty in Myocardial Infarction Trial
Why I Prefer Ticagrelor
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.
Duration of Dual Antiplatelet Therapy
Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.
What oral antiplatelet therapy would you choose?
For the ACTION study group
The Challenge of AF and PCI: Practical Strategies to Improve Outcomes
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
Roberta Rossini et al. JCIN 2018;11:
ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.
Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.
TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.
Primary safety endpoint
OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.
The Case for Routine CYP2C19 ( Plavix® ) Genetic Testing
Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches.
Bleeding and Outcomes OASIS Registry, OASIS - 2, CURE (n=34,146) Death
Presentation transcript:

Gilles Montalescot, ACTION Study Group, Paris Safer stents and strategies: is it time for the de-escalation of dual antiplatelet treatment regimes? Aspirin after stenting - Do we still need it? Gilles Montalescot, ACTION Study Group, Paris

Duration de-escalation after DES STENT SENIOR study (n=1200) Death, MI, Stroke and TLR Varenne O et al. Lancet 2017 ZEUS study (n=1606) LEADERS-FREE study (n=2466) Valgimigli M et al. JACC 2015 Urban P et al. NEJM 2015

P2Y12 de-escalation after ACS Death, Urg. revasc, Stroke, BARC>2 BARC > 2

Aspirin de-escalation with OAC WOEST PIONEER REDUAL The Times They Are A Changin N. Hammoudi, G. Montalescot 2017 2018

REMOVING/REPLACING ASA in non-PCI patients

Head-to-head comparisons with ASA Study n population Drug Efficacy Safety

REMOVING ASA in PCI patients

Removing ASA in patients with previous PCI undergoing noncardiac surgery POISE-2 n=234 aspirin therapy n=236 placebo Patients with prior PCI (90% stent) Major Bleeding Death or non fatal MI p=0.036 p=0.73 Ann Intern Med. 2018 Feb 20;168(4):237-244.

What have we learnt from clopidogrel removal (keeping ASA) after PCI? Absolute changes  1–2% of MACE 1% of MB Neutral on death

Can we do better with ticagrelor/prasugrel when ASA is removed? N Engl J Med 2017; 376:32-40

REMOVING ASA AFTER PCI ?

Why de-escalate? Not in all PCI patients! ASA (75-100mg) + P2Y12 antagonist for 3-12 months Ongoing or recent major bleeding Prior Hx of ICH Prior Hx of any major bleeding HBR (PRECISE-DAPT>25) Elderly Scheduled surgery Profession at risk of bleeding Socio-economic Why de-escalate? Not in all PCI patients!

How de-escalate? ASA (75-100mg) + ticagrelor (90 bid) or prasugrel (10mg od) for 12 months Reduce dose of ticagrelor or prasugrel Reduce duration of DAPT Switch ticagrelor or prasugrel to clopidogrel Stop ASA early Platelet function testing PEGASUS PRASFIT PRODIGY RESET EXCELLENT MASTERDAPT COBRA-REDUCE TOPIC WOEST PIONEER REDUAL GLOBAL-LEADERS TWILIGHT ANTARCTIC TROPICAL-ACS

Global-leaders All 1 mth Ticagrelor 2 yrs Death/MI

Global-Leaders Death or MI BLEEDING ESC 2018

TWILIGHT Elective 3 mths Ticagrelor 1 year Bleeding

 ? Removing ASA after PCI ticagrelor clopidogrel Study n Drug left Efficacy Safety ticagrelor  ? clopidogrel

The other benefits of aspirin J Am Coll Cardiol 2015;66:74–85

ADD-Aspirin trial Capodanno et al. Nat Rev Cardiol. 2018 Aug;15(8):480-496. 

Aspirin after stenting - Do we still need it? Yes, in the first month, for routine PCI Yes, in the first 6 months in ACS or high ischemic risk patients, No, beyond 1-3 months in high bleeding risk patients Otherwise, randomize in the ongoing studies!

Thank you! Slides available at www.action-coeur.org Silvain J. JACC 2011;57:1359-67 Slides available at www.action-coeur.org